Results:
For high risk clinical target volume (HR CTV) the median was volume 37.4 cm3 (range; 15.3-76.1 cm3) and the median of D90 was 85.3Gy (range; ). The median of D2cc for bladder, rectum, sigmoid, and bowel loop were 84Gy (range; 68.3-89.7Gy), 66.1Gy (range; 56.8-76.3Gy), 65.6 (range; 49-77.1Gy), and 61.9Gy (range; 45.8-78.1Gy), respectively. 81.2% (95 of 117 plans) were performed using VariSourceTM ring applicator with 'Siriraj Ring Cap' extension, while mean of coverage of the HR CTV was 89.2% (range; 57-99%). 18.8% (22 of 117 plans) were applied using tandem with ovoids, and mean of coverage of the HR CTV was 79.9% (range; 53-96%). Median follow up was 10.6 months. The actuarial 1 year loco-regional recurrence free survival rate was 90.5% (95% confidence interval (CI); 67-98%), progression free survival rate was 85.7% (95% CI; 62-95%), and overall survival rate was 95.4% (95% CI; 71-99%). One patient had a grade 2 late rectal complication. No grade 3-5 late complications have been recorded so far.
Conclusion:
IGBT with or without hybrid technique using VariSourceTM titanium ring applicator with 'Siriraj Ring Cap' extension is applicable for locally advanced cervical cancer resulting in an excellent local control rate and limited morbidity. Purpose or Objective: The effectiveness of radiation therapy in the management of cervical cancer of all stages is well established. Radiation therapy usually consists of a combination of external beam therapy and brachytherapy. Further exploration of new approaches and methodologies is a promising direction of development. Given the radiobiological aspects and an important economic factor, i.e. reduction of hospital stay. The aim of this study was to estimate the effectiveness of the treatment of cervical cancer patients using adaptive image-guided brachytherapy (IGBT) during split course.
EP-1972 Application of adaptive brachytherapy in the treatment of cervical cancer in accelerated mode

Material and Methods:
In the period from May 2014, 38 patients with primary cervical cancer were treated with combined radiotherapy using the new split-adaptive methodology for IGBT. We used conformal radiation techniques: BOX method, IMRT or RapidArc. Total dose on the pelvic area and regional metastases was 50 Gy. Further HDR IGBT brachytherapy was followed with dosimetry planning MRI -images. The treatment was on 1st and 2nd , 8th and 9th days, ring tandem applicators implantation under general anesthesia. Between the fractions 1 and 2 and 3 and 4, the patients were with applicator under the supervision of medical staff during the day. Monitoring planning was conducted according to MRI-studies; as a result treatment plan was composed for every 2 fractions. The position of the applicator in relation to the tumor and critical organs during the day doesn't change provided that the methodology is being correctly observed. Dose plans were optimized for maximal tumor dose (D90) and coverage (V100 and V80). The dose parameters in the target volume are the following: D 90 = 7.3 (5.9-9.1) Gy, V 100 = 91.5 (79.2-99.1) %, V 80 = 97.8 (90.5 -100). Of the patients it was T2bN0M0 -7 patients, T3bN0M0 -5, T2b-3bN1M0 -18, T2b-3bN1M1 -8.
Results: in the results the values of dose rates (D 2 cc / D 0,1 cc) to organs of risk (bladder, rectum and sigmoid) are the following: 3.7 (1.7-7) / 4.8 (2.2 -9.4) Gy; 3.1 (1.2-6) / 4.2 (1.4 -8.3) and 3.9 (2.2-5.7) / 5.5 (3.5 -7.6) Gy. During follow-up time for 12 months no any acute or late toxicity of grade 2 were observed and not observed any difference in comparison with the fractionation scheme used previously. No one local recurrence were observed, regional recurrence in 2 (2 and 7 months), distant metastasis in 1 (12 months). The patients have undergone the treatment satisfactorily. The number of surgical implantations decreases from 4 to 2. According to preliminary data, local radiation reactions are not multiple.
Conclusion:
The main advantage of this method is the dose delivery in a shorter period of time, which allows for a greater control of the tumor. This method allows to reduce the time of course of brachytherapy to 9 days. Evaluating the effectiveness of treatment shows good tolerance of this treatment with satisfactory results. This clinical study is currently ongoing. pelvic-paraaortic lymphadenectomy. Treatment: pelvic(+/-)para-aortic3D/IMRT radiotherapy(45Gy) and weekly cisplatin followed by HDR-BQ and pelvic node/ parametrial boost 60Gy. Two implants at week 6th and 7 th were done: 5 fractions of 6Gy and from 2011 4 fractions of 7Gy. MRI/TAC was done in each implant. There where defined: GTV, CTH-HR, CTV-IR; OAR: rectum, bladder and sigmoid.
EP-1973 MRI-guided brachytherapy and 3D/IMRT radiotherapy for cervical carcinoma. A prospective study
Results:
Patients: T1b2-T2a: 3p, T2b 36p, T3a: 2p; T3B 9p; N0: 31p, N1 19p.With a median follow up of 50.6 months(8.1 -89.2 months), 5 patients had local recurrence, 6 lymph node recurrence, 6 distant metastasis and 36 without recurrence. Local control at 5 years was 88%; Ib2-IIB: 93%, III: 70%. (p:0.07). Lymph node Regional Disease Free Survival(RDFS) 5y was 88%; IB2-IIB: 89%, III: 83% (p:ns); for pN0: 94%; pN+ iliac-paraaortic: 77% (p: 0.08). Metastasis Free Survival 5y was 78%; IIBN0: 78%, IIBN1: 89%, III: 63%. Overall
